News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mallinckrodt Inc. Announces Approval of New Gablofen® Prefilled Syringe


1/22/2013 10:00:30 AM

HAZELWOOD, Mo.--(BUSINESS WIRE)--Mallinckrodt, the Pharmaceuticals business of Covidien (NYSE: COV), today announced the U.S. Food and Drug Administration (FDA) approval of Gablofen® (baclofen injection) in prefilled syringes. The Gablofen prefilled syringe was created to reduce preparation steps, helping to simplify the pump refill process for patients receiving ITB TherapySM (Intrathecal Baclofen Therapy) to treat severe spasticity of cerebral and spinal origin. “The launch of Gablofen prefilled syringe enhances our product portfolio and provides a known treatment in a convenient delivery technology,” said Mark Trudeau, President, Mallinckrodt. “The prefilled syringe has the opportunity to replace the traditional glass ampules and simplify the pump refill process for healthcare providers treating appropriate patients with severe spasticity.”

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES